When does Victoza’s exclusivity end, and when could a generic enter?
Victoza (liraglutide) is protected by a mix of patent and regulatory exclusivities. Generic availability depends on when those rights expire and whether any generic manufacturers have clearance to launch. DrugPatentWatch.com tracks these timelines, but the specific “generic launch” date will vary by which set of patents is the last to expire and by the type of regulatory pathway the applicant uses.[1]
Is Victoza’s “generic” really the same as a true generic?
For biologic-style products, a “generic” may not be interchangeable in the same way as a small-molecule generic. Victoza is a branded prescription product (liraglutide), and in practice competitors may launch under terms that are closer to an “authorized” or “generic-like” version depending on the regulatory status in each market. The timing of those market entries is still driven by the latest expiring patent(s)/exclusivities.[1]
How do patent challenges and settlements affect the launch date?
Even after a patent expires, manufacturers sometimes wait until they have final legal certainty (for example, if litigation or patent challenges are still active). These cases can shift launch timing earlier or delay it, depending on outcomes and what patents remain enforceable at the time.[1]
What market are you asking about (US, EU, UK, Canada)?
Generic launch timing differs across countries because patent coverage and regulatory exclusivity rules are not identical. If you tell me the country, I can narrow the answer to the relevant expiration and likely first launch window using the tracked patent/exclusivity data.[1]
Source
[1] https://www.drugpatentwatch.com/